Transgenic flies expressing tau and amyloid precursor fragment
AssigneeEn Vivo Pharmaceuticals, Inc.
InventorsChristopher Cummings, Matthew Mahoney, Carol Singh
Life of this patent
Estimating the term…
Abstract
The present invention discloses a transgenic fly that expresses a carboxy terminal fragment of the human amyloid-β precursor protein (APP) and a double transgenic fly that expresses both the fragment of APP and tau protein. The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Claims33
A transgenic Drosophila whose genome comprises a first DNA sequence shown in SEQ ID NO:1, a second DNA sequence shown in SEQ ID NO:16, and a third DNA sequence encoding Gal4, wherein said first DNA sequence is fused to a DNA sequence shown in SEQ ID NO:5 and said third DNA sequence is operatively linked to an elav promoter.
A transgenic fly whose genome comprises a first DNA sequence that encodes a carboxy terminal fragment of human amyloid precursor protein, and a second DNA sequence that encodes a tau protein, wherein each of said first and second DNA sequences is operatively linked to an expression control sequence.
A transgenic fly whose genome comprises a DNA sequence that encodes a mutant carboxy terminal fragment of human amyloid precursor protein, wherein the DNA sequence is operatively linked to an expression control sequence, and wherein the mutant carboxy terminal fragment of human amyloid precursor protein is not the London mutant.
Dependencies are inferred from the claim text.